Prenosis, Inc.
Chicago, IL Prenosis, Inc.
- UEI
- F4S5H4BLMZL5
- CAGE
- 75AY2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- Iitri Center, 3440 S Dearborn St 216 s, Chicago, IL 60616, USA
- Website
- prenosis.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Prenosis, Inc.
Prenosis, Inc. is a Chicago-based corporate entity specializing in advanced medical research, analytics, and diagnostic services focused on infectious diseases, particularly sepsis and acute respiratory conditions. Registered in SAM.gov since 2014, the company is a self-certified small disadvantaged business that develops sophisticated technological platforms combining clinical data, biomarkers, and AI-enabled tools for precision medicine. The company's core competency involves creating innovative diagnostic and predictive analytics solutions for complex medical challenges, with a specific emphasis on developing point-of-care systems that can characterize and stratify patient responses to infections.
Prenosis, Inc. has secured multiple federal contract awards from agencies like the Department of Health and Human Services and the Defense Threat Reduction Agency. These contracts, totaling approximately $25 million, primarily focus on developing predictive analytics systems and conducting research to predict disease severity due to infection. The $20 million contract with the Office of the Assistant Secretary for Preparedness and Response involves expanding their Immunix platform for precision medicine in severe acute respiratory infections and ARDS. Another $749,000 contract supports a 3-site clinical study to assess the feasibility of implementing the Sepsis Immunoscore diagnostic test in hospital environments. The contracts are not set-aside and demonstrate the company's capability to perform advanced research services for federal agencies in infectious disease and emergency preparedness domains.
Prenosis, Inc. has received multiple federal grants from the National Institute of General Medical Sciences, focusing on sophisticated medical research projects. These grants, collectively supporting the development of their Immunix platform, involve comprehensive studies on sepsis and host response mechanisms. The grant projects include clinical validation of a point-of-care precision medicine endotyping platform, analyzing combined biomarker and electronic medical record data for understanding heterogeneous treatment effects, and constructing time trajectory host response maps. Each grant leverages Prenosis' extensive biobank, which contains over 91,000 biospecimens from more than 23,000 infection patients across 10 U.S. hospital sites. The research involves measuring 40-43 protein biomarkers, integrating clinical data through advanced AI technologies, and developing innovative approaches to understanding and classifying patient responses to serious infections.
Quick answers
What is Prenosis, Inc.'s UEI?
Prenosis, Inc.'s Unique Entity ID (UEI) in SAM.gov is F4S5H4BLMZL5.
What is Prenosis, Inc.'s CAGE code?
Prenosis, Inc.'s CAGE code is 75AY2.
What is Prenosis, Inc.'s primary NAICS code?
Prenosis, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Prenosis, Inc. located?
Prenosis, Inc.'s physical address in SAM.gov is Iitri Center, 3440 S Dearborn St 216 s, Chicago, IL 60616, USA.
Is Prenosis, Inc. registered in SAM.gov?
Yes. Prenosis, Inc.'s SAM.gov registration is active through February 2, 2027.
What is Prenosis, Inc.'s most recent federal award?
Prenosis, Inc.'s most recent federal grant award is Derivation and validation of the heart failure cardioscore: an AI diagnostic for heartfailure using novel biomarkers and… (R44HL180159), from National Heart Lung and Blood Institute, on September 1, 2026.
On GovTribe
See Prenosis, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors